Pipeline Watch
30 November 2008
This week’s Pipeline Watch table records the start of another Phase III study for GlaxoSmithKline’s novel multitargeted anticancer pazopanib (Armala). The tyrosine kinase receptor inhibitor for VEGFr-1, -2, -3, PDGFR-alpha and beta and c-kit, which is currently awaiting EU and US approval...
Please Login to read the full article.
30 November 2008
This week’s Pipeline Watch table records the start of another Phase III study for GlaxoSmithKline’s novel multitargeted anticancer pazopanib (Armala). The tyrosine kinase receptor inhibitor for VEGFr-1, -2, -3, PDGFR-alpha and beta and c-kit, which is currently awaiting EU and US approval...
Please Login to read the full article.
RELATED CONTENT
NEWS
- GSK expands tiered pricing approach in India with Votrient and Revolade launches
- FDA reviewers question efficacy of Pfizer's kidney cancer drug ahead of ODAC
- NICE drug wars: Tarceva vs Iressa, Revlimid vs IFN alpha, Botox vs SoC, and others
- ODAC backs Pfizer kidney cancer drug as second-line treatment
COMMENT
Other Informa Comment
EVENTS
09 February 2012
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
